There have been no open-market insider trades at Apimeds Pharmaceuticals US, Inc. in the last 12 months.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. On the institutional side, 7 funds reported holding APUS at the end of Q2 2026, and funds were split between buying and selling.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 15, 2025 | Kim Christopher | Chair | Buy | 7,730 | $1.86 | $14K | SEC |
| May 15, 2025 | Kim Christopher | Chair | Buy | 19,770 | $1.82 | $36K | SEC |
| May 14, 2025 | Koo Jakap | Director | Buy | 28,500 | $1.99 | $57K | SEC |
| May 14, 2025 | Inscobee Inc. | 10% Owner | Buy | 500,000 | $4.00 | $2.0M | SEC |
There were no open-market insider trades in APUS in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
7 investment managers reported holding APUS in SEC Form 13F filings for Q2 2026.
No congressional trades in APUS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).